Dr. Timothy McGraw

A multidisciplinary team of Weill Cornell Medicine researchers has received a five-year $5.7 million grant from the National Cancer Institute at the National Institutes of Health to fund a center aimed at developing messenger RNA (mRNA) vaccines to deter cancer development in at-risk groups.

Tumors can use an enzyme called ART1 to thwart antitumor immune cells, making the enzyme a promising new target...

A prestigious Cancer Moonshot grant from the National Cancer Institute’s Immuno-Oncology Translational Network will enable investigators to explore the mechanisms that allow slow-growing lung cancer lesions to progress into aggressive malignancies and identify new therapeutic strategies to intercept the transition. 

The goal of the Dean’s Inaugural Symposium on Opportunities for Entrepreneurship and Academic Drug Development, hosted at Weill Cornell Medicine’s Uris Auditorium, was to highlight the resources available to investigators to help them turn their research findings into new treatments and therapies for patients.

Weill Cornell Medical College and drug maker UCB have teamed up to translate innovative Weill Cornell-led research in bone disorders, metabolic disease and genetics into next-generation treatments.

The Rab10 Protein Helps Regulate the Uptake of Glucose Into Cells, According to Weill Cornell Medical College Study NEW YORK (April 3, 2007) — Scientists at Weill Cornell Medical College have identified a protein called Rab10 as an important partner...

A $1.5 million grant from the W.M. Keck Foundation has established a new research and training program—called Cellular and Molecular Biophysics of Signal Transduction—to be conducted jointly by Weill Medical College and Cornell University in Ithaca. Through this new...